– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to ...

BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...